We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
+19.47%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$285M
AUM Growth
-$8.04M
Cap. Flow
-$34.5M
Cap. Flow %
-12.13%
Top 10 Hldgs %
60.71%
Holding
48
New
9
Increased
9
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$12M
2
AVBP icon
ArriVent BioPharma
AVBP
+$4.49M
3
FENC icon
Fennec Pharmaceuticals
FENC
+$4.41M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$3.86M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$2.49M

Top Sells

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$14.2M
2
CYTK icon
Cytokinetics
CYTK
+$12.7M
3
VRNA
Verona Pharma
VRNA
+$10.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$9.52M
5
GUTS icon
Fractyl Health
GUTS
+$7.43M

Sector Composition

Rank Sector Weight
1 Healthcare 96.46%
2 Miscellaneous 3.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$567M
$33M 11.6%
3,300,389
– –
SVRA icon
2
Savara
SVRA
$1.08B
$20.5M 7.21%
3,403,721
-596,279
-15% -$2.92M
FENC icon
3
Fennec Pharmaceuticals
FENC
$430M
$20.1M 7.07%
2,613,508
+536,668
+26% +$4.41M
XERS icon
4
Xeris Biopharma Holdings
XERS
$1.55B
$16.6M 5.83%
2,111,700
+315,934
+18% +$2.49M
VRDN icon
5
Viridian Therapeutics
VRDN
$2.61B
$14M 4.92%
450,000
-150,000
-25% -$4.11M
MDWD icon
6
MediWound
MDWD
$163M
$13.8M 4.86%
749,054
– –
VSTM icon
7
Verastem
VSTM
$654M
$13.8M 4.85%
1,788,475
-141,088
-7% -$1.26M
REPL icon
8
Replimune Group
REPL
$1.46B
$13.7M 4.82%
+1,410,497
New +$12M
ATYR
9
aTyr Pharma
ATYR
$53M
$13.6M 4.78%
1,039,080
– –
HELP
10
Cybin Inc
HELP
$890M
$13.6M 4.77%
1,657,540
+157,540
+11% +$1.01M
EYPT icon
11
EyePoint Inc
EYPT
$386M
$12.6M 4.43%
690,000
+40,000
+6% +$567K
CGON icon
12
CG Oncology
CGON
$6.59B
$12.5M 4.38%
300,000
– –
CYTK icon
13
Cytokinetics
CYTK
$10B
$12.4M 4.36%
195,045
-204,955
-51% -$12.7M
XFOR icon
14
X4 Pharmaceuticals
XFOR
$401M
$10.4M 3.66%
2,605,920
+1,061,313
+69% +$3.86M
DFTX
15
Definium Therapeutics
DFTX
$5.51B
$10M 3.53%
750,000
– –
PROF
16
Profound Medical
PROF
$250M
$8.41M 2.96%
1,068,955
+376,770
+54% +$2.42M
NSPR icon
17
InspireMD
NSPR
$39.8M
$6.95M 2.44%
3,905,743
– –
OCUL icon
18
Ocular Therapeutix
OCUL
$2.28B
$4.86M 1.71%
400,000
– –
AVBP icon
19
ArriVent BioPharma
AVBP
$1.49B
$4.34M 1.53%
+215,871
New +$4.49M
TLPH icon
20
Talphera
TLPH
$62.3M
$4.08M 1.43%
3,579,273
-806,484
-18% -$972K
MYO icon
21
Myomo
MYO
$63.4M
$3.49M 1.23%
3,839,772
+48,984
+1% +$47K
QQQ icon
22
PUT
Invesco QQQ Trust
QQQ
$489B
$3.03M 1.06%
450,000
+200,000
+80% +$123M
PYPD icon
23
PolyPid
PYPD
$103M
$3.02M 1.06%
696,556
-222,112
-24% -$825K
OKUR
24
OnKure Therapeutics
OKUR
$153M
$2.12M 0.74%
+730,488
New +$2.19M
SPY icon
25
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$1.89M 0.66%
510,000
+210,000
+70% +$142M
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.2% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Rosalind Advisors held 48 positions worth $285M, down 2.7% from $293M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Rosalind Advisors withdrew a net $34.5M in Q4 2025, closing 9 positions and reducing 10 holdings. Its most notable exit was Rezolute, an estimated $14.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

Against the trend, Rosalind Advisors opened a new position in Replimune Group worth $13.7M.

  • Rosalind Advisors's largest Q4 2025 buy was Replimune Group: 1,410,497 shares worth $13.7M.
  • Rosalind Advisors added most to Fennec Pharmaceuticals in Q4 2025, an estimated $4.41M increase.
  • Rosalind Advisors's biggest Q4 2025 reduction was Cytokinetics, cutting an estimated $12.7M.
  • Rosalind Advisors fully exited Rezolute in Q4 2025, selling an estimated $14.2M.
  • Rosalind Advisors's ten largest holdings make up 61% of its $285M portfolio in Q4 2025.
  • Rosalind Advisors opened 9 new positions and closed 9 in Q4 2025.
  • Rosalind Advisors's portfolio value fell 2.7% quarter-over-quarter to $285M.

Based on Rosalind Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.